Cellular Therapies in Solid Tumors: Are We Ready for Primetime?

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Adoptive cellular immunotherapy (ACT) has transformed hematologic cancer treatment but faced challenges in solid tumors.
• Recent FDA approvals of lifileucel (TIL therapy) and afamitresgene autoleucel (TCR therapy) signify a breakthrough for solid tumors.
• Multiple ACT platforms are under investigation for diverse solid tumor indications.

Purpose of the Study:

• To provide a practice-oriented framework for understanding emerging ACT platforms for solid tumors.
• To discuss clinical data, toxicity considerations, and implementation strategies for ACT in oncology.
• To highlight the evolving landscape of cellular therapies in solid tumor treatment.

Main Methods:

• Review of recent FDA approvals and ongoing clinical investigations of various ACT platforms (TIL, TCR, CAR-T, CAR-NK, CAR-macrophage).
• Analysis of key barriers to ACT efficacy in solid tumors, including tumor trafficking, antigen heterogeneity, and the tumor microenvironment.
• Discussion of advancements in cellular engineering, such as armored constructs, logic-gated strategies, and novel manufacturing approaches.

Main Results:

• Significant advancements in ACT for solid tumors, evidenced by recent FDA approvals for melanoma and synovial sarcoma.
• Identification of critical barriers to ACT efficacy, including tumor microenvironment and cellular persistence.
• Development of innovative cellular engineering strategies and manufacturing techniques to enhance ACT effectiveness.

Conclusions:

• ACT is emerging as a viable treatment modality for select solid tumors, necessitating careful patient selection and multidisciplinary care.
• Understanding and managing ACT-specific toxicities and logistical requirements are crucial for successful implementation.
• Continued research and development in ACT platforms and engineering hold promise for expanding its application in solid tumor oncology.